ScholarIQanswers from OpenAlex

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective

PaperCitations, authors & open-access status

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective have?

ScholarIQcitation count

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective has 35 citations in the OpenAlex counts ScholarIQ stores.

When was Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective published?

ScholarIQyear

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective has 2024 year in the ScholarIQ index.

What is the open-access status of Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective?

ScholarIQoa status

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective has gold oa status in the ScholarIQ index.

What is the DOI of Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective?

ScholarIQdoi

The DOI for Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective is on the source record.

What is the PMID of Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective?

ScholarIQpmid

The PMID for Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective is on the source record.

What is the OpenAlex record for Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective?

ScholarIQopenalex

The OpenAlex for Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial